Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alpha Cognition Inc. - Common Stock (NQ:ACOG)

9.655 +0.525 (+5.75%)
Streaming Delayed Price Updated: 2:46 PM EDT, Aug 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 24,400
Open 9.100
Bid (Size) 9.550 (1)
Ask (Size) 9.770 (9)
Prev. Close 9.130
Today's Range 9.090 - 9.780
52wk Range 3.750 - 11.54
Shares Outstanding 146,925,149
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Alpha Cognition to Report Second Quarter 2025 Financial Results and Operating Overview
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition Announces Partner China Medical System Has NDA Accepted in China for the Review of ZUNVEYL® (Benzgalantamine) for Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire

Performance

YTD
+70.3%
+70.3%
1 Month
-9.5%
-9.5%
3 Month
+30.5%
+30.5%
6 Month
+63.6%
+63.6%
1 Year
+69.4%
+69.4%

More News

Read More
Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer’s Association International Conference
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition Announces Positive Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury
From Alpha Cognition Inc.
Via Business Wire
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q1 2025
Via Newsfile
Topics Intellectual Property
Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview
From Alpha Cognition Inc.
Via Business Wire
Earnings Scheduled For May 15, 2025
Via Benzinga
Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer’s Association International Conference
From Alpha Cognition
Via Business Wire
Why ServiceNow Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens
From Alpha Cognition Inc.
Via Business Wire
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024
Via Newsfile
Topics Intellectual Property
Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
From Alpha Cognition Inc.
Via Business Wire
Earnings Scheduled For March 31, 2025
Via Benzinga
Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition Is 'Under-Followed' As Alzheimer Drug Targets $2 Billion Long Term Care Market: Analyst
Via Benzinga
This West Pharmaceutical Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s disease
From Alpha Cognition Inc.
Via Business Wire
Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG)
Via Newsfile
OTC Markets Group Announces Quarterly Index Performance and Rebalancing
From OTC Markets
Via GlobeNewswire
Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL
From Alpha Cognition Inc.
Via Business Wire
Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China
Via Benzinga
Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China
From Alpha Cognition, Inc.
Via Business Wire
Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call
From Alpha Cognition Inc.
Via Business Wire

Frequently Asked Questions

Is Alpha Cognition Inc. - Common Stock publicly traded?
Yes, Alpha Cognition Inc. - Common Stock is publicly traded.
What exchange does Alpha Cognition Inc. - Common Stock trade on?
Alpha Cognition Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Alpha Cognition Inc. - Common Stock?
The ticker symbol for Alpha Cognition Inc. - Common Stock is ACOG on the Nasdaq Stock Market
What is the current price of Alpha Cognition Inc. - Common Stock?
The current price of Alpha Cognition Inc. - Common Stock is 9.655
When was Alpha Cognition Inc. - Common Stock last traded?
The last trade of Alpha Cognition Inc. - Common Stock was at 08/08/25 02:46 PM ET
What is the market capitalization of Alpha Cognition Inc. - Common Stock?
The market capitalization of Alpha Cognition Inc. - Common Stock is 1.42B
How many shares of Alpha Cognition Inc. - Common Stock are outstanding?
Alpha Cognition Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.